Macromolecular antioxidants based on sterically hindered phenols and phosphites

Abstract
Sterically hindered phenol and phosphite based compounds represented by structural formula II:
Description
BACKGROUND OF THE INVENTION

Antioxidants are employed to prevent oxidation in a wide range of materials, for example, plastics, elastomers, lubricants, petroleum based products (lubricants, gasoline, aviation fuels, and engine oils), cooking oil, cosmetics, processed food products, and the like. While many small molecule antioxidants exist, there is a continuing need for new antioxidants that have improved properties.


The commercial use of triaryl phophites in latex is well known. Triaryl phophites containing alkyl-substituted phenyl rings have been found to be effective synthetic latex stabilizers. However, there is a continuing need for antioxidants with higher antioxidant activity and higher thermal stability.


SUMMARY OF THE INVENTION

The present invention relates to high performance, sterically hindered, phenol and phosphite based macromolecular antioxidants. In certain embodiments, the sterically hindered, phenol and phosphite based macromolecules of the present invention have enhanced antioxidant activity and better thermal stability compared to commercially available antioxidants.


In particular, the present invention pertains to sterically hindered phenol and phosphite based compounds represented by a formula selected from I-III:




embedded image


R is:




embedded image


R1 and R2 in each occurrence, independently is an optionally substituted alkyl, an optionally substituted aryl or an optionally substituted aralkyl.


X and Y in each occurrence, independently is a bond, —O—, —NH—, —C(O)NH—, —NHC(O)—, —C(O)O—, —OC(O)— or —CH2—.


n and m in each occurrence, is independently 0 or a positive integer.


i and j in each occurrence, independently is 0, 1, 2, 3 or 4.


R″ is an optionally substituted alkyl.


In another embodiment, the present invention pertains to methods of preventing oxidation. The method comprises combining an oxidizable material with a compound represented by a structural formula selected from I-III.


In yet another embodiment, the present invention pertains to methods for preparing sterically hindered phenol and phosphite based compound, having a formula selected from I-III. The method comprises combining a phenol containing compound with a phosphorous containing compound, such as, phosphorous trichloride in a suitable solvent under conditions suitable for reaction of the phenol containing compound with the phosphorous containing compound.


In yet another embodiment the present invention pertains to the use of the disclosed compounds as antioxidants in a wide range of materials including, but not limited to, food, plastics, elastomers, composites and petroleum based products.


The compounds of the invention provide significant oxidative resistance and thermal stability. The compounds of the invention generally have higher oxidative induction time, higher thermal stability and lower change of Melt flow or viscosity than commercially available antioxidants Without wishing to be bound by theory it is believed that the enhanced molecular activity comes from the synergistic chemistry between the two main integral components (phenolic and phosphite components) of these macromolecular antioxidants.


In certain embodiments, the compounds disclosed herein, do not discolor the substance to which they are added. In certain other embodiments the compounds disclosed herein impart fewer odors to the substance to which they are added than currently available antioxidants. In certain other embodiments, the disclosed compounds provide enhanced oven aging properties to organic materials subject to attack by heat and oxygen. In certain other embodiments the disclosed compounds have higher antioxidant activity and higher thermal stability than antioxidants which are currently known or used in the art.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1, is a comparison of the Oxidative Induction Time (OIT) of one embodiment of the invention, namely, tris[N-(4-hydroxyphenyl),-3-(2,6-di-tert.-butyl,4-hydroxyphenyl)propionamide]phosphate, versus commercially available Irganox®.



FIG. 2 is the Fourier Transform Infrared (FT-IR) spectrum of tris[N-(4-hydroxyphenyl),-3-(2,6-di-tert.-butyl, 4-hydroxyphenyl)propionamide]phosphate of the invention.



FIG. 3 is the Ultraviolet (UV) spectrum of tris[N-(4-hydroxyphenyl),-3-(2,6-di-tert.-butyl,4-hydroxyphenyl)propionamide]phosphate of the invention.



FIG. 4 is the Thermogravimetric Analysis (TGA) of tris[N-(4-hydroxyphenyl),-3-(2,6-di-tert.-butyl, 4-hydroxyphenyl)propionamide]phosphate of the invention.





DETAILED DESCRIPTION OF THE INVENTION

The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention.


In one embodiment, the present invention pertains to sterically hindered phenol and phosphite based compounds, represented by a formula selected from I-III:




embedded image


R is:




embedded image


R1 and R2 in each occurrence, independently is an optionally substituted alkyl, optionally substituted aryl or optionally substituted aralkyl. In one embodiment, each R1 and R2 are independently an optionally substituted alkyl. In another embodiment, each R1 and R2 are independently a C1-C6 alkyl.


In one embodiment R is:




embedded image


In another embodiment R is:




embedded image


In yet another embodiment R is:




embedded image


X and Y in each occurrence independently is a bond, —O—, —NH—, —C(O)NH—, —NHC(O)—, —C(O)O—, —OC(O)— or —CH2—. In one embodiment, X and Y in each occurrence independently is a bond or —CH2—. In another embodiment. X and Y in each occurrence independently is a bond, —O— or —CH2—. In yet another embodiment, X and Y in each occurrence independently is a bond, —NH— or —CH2—. In yet another embodiment, X and Y in each occurrence independently is a bond, —C(O)NH— or —CH2—. In yet another embodiment, X and Y in each occurrence independently is a bond, —NHC(O)—, or —CH2—. In yet another embodiment, X and Y in each occurrence independently is a bond, —C(O)O— or —CH2—. In yet another embodiment, X and Y in each occurrence independently is a bond, —OC(O)— or —CH2—.


n and m in each occurrence independently is 0 or a positive integer. In one embodiment, n and m in each occurrence independently is 0 to 18. In another embodiment, n and m in each occurrence independently is 0 to 12. In yet another embodiment, n and m are in each occurrence independently is 0 to 6.


i and j in each occurrence independently is 0, 1, 2, 3 or 4. In one embodiment i and j in each occurrence independently is 0, 1 or 2. In a particular embodiment, i is 0. In another particular embodiment j is 2.


R″ is an optionally substituted alkyl. In one embodiment R″ is C1-C6 alkyl.


In one embodiment the present invention pertains to compounds represented by structural formula I.


In one embodiment the present invention pertains to compounds represented by structural formula II.


In one embodiment the present invention pertains to compounds represented by structural formula III.


In a particular embodiment, for compounds of the present invention represented by structural formulas I-III, R is:




embedded image



and n and m in each occurrence independently is 0 to 12, and the remainder of the variables are as described above for structural formulas I-III.


In another particular embodiment, for compounds of the present invention represented by structural formulas I-III, R, n and m are as described immediately above, and R1 and R2 in each occurrence, independently is an optionally substituted alkyl; i and j in each occurrence independently is 0, 1 or 2; and the remainder of the variables are as described above for structural formulas I-III.


In yet another particular embodiment, for compounds of the present invention represented by structural formulas I-III, R1, R2, i and j are as described immediately above, and R is:




embedded image



n and m in each occurrence, independently is 0 to 6; and the remainder of the variables are as described above for structural formulas I-III.


In another particular embodiment, for compounds of the present invention represented by structural formulas I-III, R1, R2, i, j, R, n and m are as described immediately above, and X and Y in each occurrence, independently is a bond or —CH2—; and the remainder of the variables are as described above for structural formulas I-III.


In another particular embodiment, for compounds of the present invention represented by structural formulas I-III, R1, R2, i, j, R, n and m are as described immediately above, and X and Y in each occurrence, independently is a bond, —O— or —CH2—; and the remainder of the variables are as described above for structural formulas I-III.


In another particular embodiment, for compounds of the present invention represented by structural formulas I-III, R1, R2, i, j, R, n and m are as described immediately above, and X and Y in each occurrence, independently is a bond, —NH— or —CH2—; and the remainder of the variables are as described above for structural formulas I-III.


In another particular embodiment, for compounds of the present invention represented by structural formulas I-III, R1, R2, i, j, R, n and m are as described immediately above, and X and Y in each occurrence, independently is a bond, —C(O)NH— or —CH2—; and the remainder of the variables are as described above for structural formulas I-III.


In another particular embodiment, for compounds of the present invention represented by structural formulas I-III, R1, R2, i, j, R, n and m are as described immediately above, and X and Y in each occurrence, independently is a bond, —NHC(O)—, or —CH2—; and the remainder of the variables are as described above for structural formulas I-III.


In another particular embodiment, for compounds of the present invention represented by structural formulas I-III, R1, R2, i, j, R, n and m are as described immediately above, and X and Y in each occurrence, independently is a bond, —C(O)O— or —CH2—; and the remainder of the variables are as described above for structural formulas I-III.


In another particular embodiment, for compounds of the present invention represented by structural formulas I-III, R1, R2, i, j, R, n and m are as described immediately above, and X and Y in each occurrence, independently is a bond, —OC(O)— or —CH2—; and the remainder of the variables are as described above for structural formulas I-III.


In an additional embodiment, for formulas I-III R is:




embedded image


n and m in each occurrence, independently is 0 or a positive integer. In one embodiment, n and m in each occurrence, independently is 0 to 1.8. In another embodiment, n and m in each occurrence, independently is 0 to 12. In yet another embodiment, n and m in each occurrence, independently is 0 to 6.


i and j in each occurrence, independently is 0, 1, 2, 3 or 4. In one embodiment, i and j in each occurrence, independently is 0, 1 or 2. In a particular embodiment, i is 0. In another particular embodiment, j is 2.


Z′ is —C(O)O—, —OC(O)—, —C(O)NH—, —NHC(O)—, —NH—, —CH═N—, —C(O)—, —O—, —S—, —C(O)OC(O)— or a bond. In one embodiment, Z′ is —C(O)O—. In another embodiment, Z′ is —OC(O)—. In yet another embodiment, Z′ is —C(O)NH—. In yet another embodiment, Z′ is —NHC(O)—. In yet another embodiment, Z′ is —NH—. In yet another embodiment, Z′ is —CH═N—. In yet another embodiment, Z′ is —C(O)—. In yet another embodiment, Z′ is —O—. In yet another embodiment, Z′ is —S—. In yet another embodiment, Z′ is —C(O)OC(O)—. In yet another embodiment, Z′ is a bond.


R′ is an optionally substituted C1-C6 alkyl, —OH, —NH2, —SH, an optionally substituted aryl, an ester or




embedded image


wherein at least one R′ adjacent to the —OH group is an optionally substituted bulky alkyl group (e.g., butyl, sec-butyl, test-butyl, 2-propyl, 1,1-dimethylhexyl, and the like).


R′1 is an optionally substituted C1-C6 alkyl, an optionally substituted aryl, an optionally substituted aralkyl, —OH, —NH2, —SH, or C1-C6 alkyl ester wherein at least one R1 adjacent to the —OH group is a bulky alkyl group (e.g., butyl, sec-butyl, tert-butyl, 2-propyl, 1,1-dimethylhexyl, and the like).).


R′2 is an optionally substituted C1-C6 alkyl, an optionally substituted aryl, an optionally substituted aralkyl, —OH, —NH2, —SH, or ester.


X′ is —C(O)O—, —OC(O)—, —C(O)NH—, —NHC(O)—, —NH—, —C(O)—, —O—, —S—, —C(O)OC(O)— or a bond. In one embodiment X′ is —C(O)O—. In another embodiment X′ is —OC(O)—. In yet another embodiment X′ is —C(O)NH—. In yet another embodiment X′ is —NHC(O)—. In yet another embodiment X′ is —NH—. In yet another embodiment X′ is —CH═N—. In yet another embodiment X′ is —C(O)—. In yet another embodiment X′ is —O—. In yet another embodiment X′ is —S—. In yet another embodiment X′ is —C(O)OC(O)—. In yet another embodiment X′ is a bond.


M′ is H, an optionally substituted aryl, an optionally substituted C1-C20 linear or branched alkyl chain with or without any functional group anywhere in the chain, or




embedded image


o is 0 or a positive integer. Preferably o is 0 to 18. More preferably o is 0 to 12. Even more preferably o is 0 to 6.


In yet another embodiment, for formulas I-III R is:




embedded image


R′2 is C1-C6 alkyl, —OH, —NH2, —SH, aryl, ester, aralkyl or




embedded image


wherein at least one R′2 is —OH, and the values and preferred values for the remainder of the variables for R are as described immediately above.


In yet another embodiment, the present invention relates to a compound of formula I-III, wherein M is




embedded image


Wherein p is 0, 1, 2, 3 or 4; and the values and preferred values for the remainder of the variables are as described above for formulas I-III.


The term “alkyl” as used herein means a saturated straight-chain, branched or cyclic hydrocarbon. When straight-chained or branched, an alkyl group is typically C1-C8, more typically C1-C6; when cyclic, an alkyl group is typically C3-C12, more typically C3-C7 alkyl ester. Examples of alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl and tert-butyl and 1,1-dimethylhexyl.


The term “alkoxy” as used herein is represented by —OR**, wherein R** is an alkyl group as defined above.


The term “acyl” as used herein is represented by —C(O)R**, wherein R** is an alkyl group as defined above.


The term “alkyl ester” as used herein means a group represented by —C(O)OR**, where R** is an alkyl group as defined above.


The term “aromatic group” used alone or as part of a larger moiety as in “aralkyl”, includes carbocyclic aromatic rings and heteroaryl rings. The term “aromatic group” may be used interchangeably with the terms “aryl”, “aryl ring” “aromatic ring”, “aryl group” and “aromatic group”.


Carbocyclic aromatic ring groups have only carbon ring atoms (typically six to fourteen) and include monocyclic aromatic rings such as phenyl and fused polycyclic aromatic ring systems in which two or more carbocyclic aromatic rings are fused to one another. Examples include 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl. Also included within the scope of the term “carbocyclic aromatic ring”, as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings (carbocyclic or heterocyclic), such as in an indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, where the radical or point of attachment is on the aromatic ring.


The term “heteroaryl”, “heteroaromatic”, “heteroaryl ring”, “heteroaryl group” and “heteroaromatic group”, used alone or as part of a larger moiety as in “heteroaralkyl” refers to heteroaromatic ring groups having five to fourteen members, including monocyclic heteroaromatic rings and polycyclic aromatic rings in which a monocyclic aromatic ring is fused to one or more other aromatic ring. Heteroaryl groups have one or more ring heteroatoms. Examples of heteroaryl groups include 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxadiazolyl, 5-oxadiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-pyrazolyl, 4-pyrazolyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-triazolyl, 5-triazolyl, tetrazolyl, 2-thienyl, 3-thienyl, carbazolyl, 2-benzothienyl, 3-benzothienyl, 2-benzofuranyl, 3-benzofuranyl, 2-indolyl, 3-indolyl, 2-quinolinyl, 3-quinolinyl, 2-benzothiazole, 2-benzooxazole, 2-benzimidazole, 2-quinolinyl, 3-quinolinyl, 1-isoquinolinyl, 3-quinolinyl, 1-isoindolyl and 3-isoindolyl. Also included within the scope of the term “heteroaryl”, as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings (carbocyclic or heterocyclic), where the radical or point of attachment is on the aromatic ring.


The term “heteroatom” means nitrogen, oxygen, or sulfur and includes any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen. Also the term “nitrogen” includes a substitutable nitrogen of a heteroaryl or non-aromatic heterocyclic group. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR″ (as in N-substituted pyrrolidinyl), wherein R″ is a suitable substituent for the nitrogen atom in the ring of a non-aromatic nitrogen-containing heterocyclic group, as defined below.


An “aralkyl group”, as used herein is an alkyl groups substituted with an aryl group as defined above.


An optionally substituted aryl group as defined herein may contain one or more substitutable ring atoms, such as carbon or nitrogen ring atoms. Examples of suitable substituents on a substitutable ring carbon atom of an aryl group include —OH, C1-C3 alkyl, C1-C3 haloalkyl, —NO2, C1-C3 alkoxy, C1-C3 haloalkoxy, —CN, —NH2, C1-C3 alkylamino, C1-C3 dialkylamino, —C(O)NH2, —C(O)NH(C1-C3 alkyl), —C(O)(C1-C3 alkyl), —NHC(O)H, —NHC(O)(C1-C3 alkyl), —C(O)N(C1-C3 alkyl)2, —NHC(O)O—(C1-C3 alkyl), —C(O)OH, —C(O)O—(C1-C3 alkyl), —NHC(O)NH2, —NHC(O)NH(C1-C3 alkyl), —NHC(O)N(C1-C3 alkyl)2, —SO2NH2—SO2NH(C1-C3alkyl), —SO2N(C1-C3alkyl)2, NHSO2H or NHSO2(C1-C3 alkyl). Preferred substituents on aryl groups are as defined throughout the specification. In certain embodiments optionally substituted aryl groups are unsubstituted


Examples of suitable substituents on a substitutable ring nitrogen atom of an aryl group include C1-C3 alkyl, NH2, C1-C3 alkylamino, C1-C3 dialkylamino, —C(O)NH2, —C(O)NH(C1-C3 alkyl), —C(O)(C1-C3 alkyl), —CO2R**, —C(O)C(O)R**, —C(O)CH3, —C(O)OH, —C(O)O—(C1-C3 alkyl), —SO2NH2—SO2NH(C1-C3alkyl), —SO2N(C1-C3alkyl)2, NHSO2H, NHSO2(C1-C3 alkyl), —C(═S)NH2, —C(═S)NH(C1-C3 alkyl), —C(═S)N(C1-C3 alkyl)2, —C(═NH)—N(H)2, —C(═NH)—NH(C1-C3 alkyl) and —C(═NH)—N(C1-C3 alkyl)2,


An optionally substituted alkyl group as defined herein may contain one or more substituents. Examples of suitable substituents for an alkyl group include those listed above for a substitutable carbon of an aryl and the following: ═O, ═S, ═NN(R**)2, ═NNHC(O)R**, ═NNHCO2 (alkyl), ═NNHSO2 (alkyl), ═NR**, spiro cycloalkyl group or fused cycloalkyl group. R** in each occurrence, independently is —H or C1-C6 alkyl. Preferred substituents on alkyl groups are as defined throughout the specification. In certain embodiments optionally substituted alkyl groups are unsubstituted.


A “spiro cycloalkyl” group is a cycloalkyl group which shares one ring carbon atom with a carbon atom in an alkylene group or alkyl group, wherein the carbon atom being shared in the alkyl group is not a terminal carbon atom.


Without wishing to be bound by any theory or limited to any mechanism it is believed that macromolecular antioxidants of the present invention exploit the differences in activities (ks, equilibrium constant) of, for example, homo- or hetero-type antioxidant moieties. Antioxidant moieties include, for example, hindered phenolic groups, unhindered phenolic groups, aminic groups and thioester groups, etc. of which there can be one or more present in each macromolecular antioxidant molecule. As used herein a homo-type antioxidant macromolecule comprises antioxidant moieties which are all same, for example, hindered phenolic, —OH groups. As used herein a hetero-type antioxidant macromolecule comprises at least one different type of moiety, for example, kindred phenolic and aminic groups in the one macromolecule.


This difference in activities can be the result of, for example, the substitutions on neighboring carbons or the local, chemical or physical environment (for example, due to electrochemical or stereochemical factors) which can be due in part to the macromolecular nature of molecules.


In one embodiment of the present invention, a series of macromolecular antioxidant moieties of the present invention with different chemical structures can be represented by W1H, W2H, W3H, . . . to WnH. In one embodiment of the present invention, two types of antioxidant moieties of the present invention can be represented by: W1H and W2H. In certain embodiments W1H and W2H can have rate constants of k1 and k2 respectively. The reactions involving these moieties and peroxyl radicals can be represented as:




embedded image



where ROO. is a peroxyl radical resulting from, for example, initiation steps involving oxidation activity, for example:

RH→R.+H.  (3)
R.+O2→ROO.  (4)


In one particular embodiment of the present invention k1>>k2 in equations (1) and (2). As a result, the reactions would take place in such a way that there is a decrease in concentration of W1. free radicals due their participation in the regeneration of active moiety W2H in the molecule according equation (5):

W1.+W2H→W1H+W2.  (5) (transfer equilibrium)


This transfer mechanism may take place either in intra- or inter-molecular macromolecules. The transfer mechanism (5) could take place between moieties residing on the same macromolecule (intra-type) or residing on different macromolecules (inter-type).


In certain embodiments of the present invention, the antioxidant properties described immediately above (equation 5) of the macromolecular antioxidants of the present invention result in advantages including, but not limited to:

    • a) Consumption of free radicals W1. according to equation (5) can result in a decrease of reactions of W1. with hydroperoxides and hydrocarbons (RH).
    • b) The regeneration of W1H provides extended protection of materials. This is a generous benefit to sacrificial type of antioxidants that are used today. Regeneration of W1H assists in combating the oxidation process The increase in the concentration of antioxidant moieties W1H (according to equation 5) extends the shelf life of materials.


In certain embodiments of the present invention, the following items are of significant interest for enhanced antioxidant activity in the design of the macromolecular antioxidants of the present invention:

    • a) The activity of proposed macromolecular antioxidant is dependent on the regeneration of W1H in equation (5) either through inter- or intra-molecular activities involving home- or hetero-type antioxidant moieties.
    • b) Depending on the rates constants of W1H and W2H it is possible to achieve performance enhancements by many multiples and not just incremental improvements.


In certain embodiments of the present invention, more than two types of antioxidant moieties with different rate constants are used in the methods of the present invention.


In certain embodiments, the present invention pertains to the use of the disclosed compounds to inhibit oxidation in an oxidizable material.


For purposes of the present invention, a method of “inhibiting oxidation” is a method that inhibits the propagation of a free radical-mediated process. Free radicals can be generated by heat, light, ionizing radiation, metal ions and some proteins and enzymes. Inhibiting oxidation also includes inhibiting reactions caused by the presence of oxygen, ozone or another compound capable of generating these gases or reactive equivalents of these gases.


As used herein the term “oxidizable material” is any material which is subject to oxidation by free-radicals or oxidative reaction caused by the presence of oxygen, ozone or another compound capable of generating these gases or reactive equivalents thereof.


Antioxidant compounds of the present invention can be used to prevent oxidation in a wide variety of compositions where free radical mediated oxidation leads to deterioration of the quality of the composition, including edible products such as oils, foods (e.g., meat products, dairy products, cereals, etc.), and other products containing fats or other compounds subject to oxidation. Antioxidant compounds can also be present in plastics and other polymers, elastomers (e.g., natural or synthetic rubber), petroleum products (e.g., fossil fuels such as gasoline, kerosene, diesel oil, heating oil, propane, jet fuel), lubricants, paints, pigments or other colored items, soaps and cosmetics (e.g., creams, lotions, hair products). The antioxidant compounds can be used to coat a metal as a rust and corrosion inhibitor. Antioxidant compounds additionally can protect antioxidant vitamins (Vitamin A, Vitamin C, Vitamin E) and pharmaceutical products from degradation. In food products, the antioxidant compounds can prevent rancidity. In plastics, the antioxidant compounds can prevent the plastic from becoming brittle and cracking.


Antioxidant compounds of the present invention can be added to oils to prolong their shelf life and properties. These oils can be formulated as vegetable shortening or margarine. Oils generally come from plant sources and include cottonseed oil, linseed oil, olive oil, palm oil, corn oil, peanut oil, soybean oil, castor oil, coconut oil, safflower oil, sunflower oil, canola (rapeseed) oil and sesame oil. These oils contain one or more unsaturated fatty acids such as caproleic acid, palmitoleic acid, oleic acid, vaccenic acid, elaidic acid, brassidic acid, erucic acid, nervonic acid, linoleic acid, eleosteric acid, alpha-linolenic acid, gamma-linolenic acid, and arachidonic acid, or partially hydrogenated or trans-hydrogenated variants thereof. Antioxidant compounds of the present invention are also advantageously added to food or other consumable products containing one or more of these fatty acids.


The shelf life of many materials and substances contained within the materials, such as packaging materials, are enhanced by the presence of an antioxidant compound of the present invention. The addition of an antioxidant compound to a packaging material is believed to provide additional protection to the product contained inside the package. In addition, the properties of many packaging materials themselves, particularly polymers, are enhanced by the presence of an antioxidant regardless of the application (i.e., not limited to use in packaging). Common examples of packaging materials include paper, cardboard and various plastics and polymers. A packaging material can be coated with an antioxidant compound (e.g., by spraying the antioxidant compound or by applying as a thin film coating), blended with or mixed with an antioxidant compound, or otherwise have an antioxidant compound present within it.


The entire teachings of each of the following applications are incorporated herein by reference:

  • Provisional Patent Application No. 60/632,893, filed Dec. 3, 2004, Title: Process For The Synthesis Of Polyalkylphenol Antioxidants, by Suizhou Yang, et al;
  • Provisional Patent Application No. 60/633,197, filed Dec. 3, 2004, Title: Synthesis Of Sterically Hindered Phenol Based Macromolecular Antioxidants, by Ashish Dhawan, et al.;
  • Provisional Patent Application No. 60/633,252, filed Dec. 3, 2004, Title: One Pot Process For Making Polymeric Antioxidants, by Vijayendra Kumar, et al.;
  • Provisional Patent Application No. 60/633,196, filed Dec. 3, 2004, Title: Synthesis Of Aniline And Phenol-Based Macromonomers And Corresponding Polymers, by Rajesh Kumar, et al.;
  • patent application Ser. No. 11/184,724, filed Jul. 19, 2005, Title: Anti-Oxidant Macromonomers And Polymers And Methods Of Making And Using The Same, by Ashok L. Cholli;
  • patent application Ser. No. 11/184,716, filed Jul. 19, 2005, Title: Anti-Oxidant Macromonomers And Polymers And Methods Of Making And Using The Same, by Ashok L. Cholli;
  • Provisional Patent Application No. 60/655,169, filed Feb. 22, 2005, Title: Nitrogen And Hindered Phenol Containing Dual Functional Macromolecules: Synthesis And Their Antioxidant Performances In Organic Materials, by Rajesh Kumar, et al.
  • Provisional Patent Application No. 60/655,169, filed Mar. 25, 2005, Title: Alkylated Macromolecular Antioxidants And Methods Of Making, And Using The Same, by Rajesh Kumar, et al.
  • Provisional Patent Application No. 60/731,125, filed Oct. 27, 2005, Title: Macromolecular Antioxidants And Polymeric Macromolecular Antioxidants, by Ashok L. Cholli, et al.
  • patent application Ser. No. 11/040,193, filed Jan. 21, 2005, Title: Post-Coupling Synthetic Approach For Polymeric Antioxidants, by Ashok L. Choll, et al.;
  • Patent Application No.: PCT/US2005/001948, filed Jan. 21, 2005, Title: Post-Coupling Synthetic Approach For Polymeric Antioxidants, by Ashok L. Cholli et al.;
  • Patent Application No.: PCT/US2005/001946, filed Jan. 21, 2005, Title: Polymeric Antioxidants, by Ashok L. Choll, et al.;
  • Patent Application No.: PCT/US03/10782, filed Apr. 4, 2003, Title: Polymeric Antioxidants, by Ashok L. Choll, et al.;
  • patent application Ser. No. 10/761,933, filed Jan. 21, 2004, Title: Polymeric Antioxidants, by Ashish Dhawan, et al.;
  • patent application Ser. No. 10/408,679, filed Apr. 4, 2003, Title: Polymeric Antioxidants, by Ashok L. Choll, et al.;


In another particular embodiment, the present invention relates to a process for preparing compounds of the present invention. Compounds of the present invention can be prepared by a one pot process, comprising the step of combining a phenol containing compound with a suitable phosphorous containing compound in a suitable solvent under conditions suitable for the reaction of the phenol containing compound with the phosphorous containing compound.


Suitable phenol containing compounds include:




embedded image


where the vales and preferred values for the variables are as described above.


Suitable phosphorous containing compounds are those which are capable of reacting with phenol containing compounds to produce compounds represented by Structural Formula I-III, including, for example, phosphorous trichloride, phosphorous pentachloride, phosphoric acid and phosphoryl trichloride.


Suitable solvents are those which do not contain any acidic protons and dissolve the starting material and the side products, but do not dissolve the end product. Examples of suitable solvents include, for example, dichloromethane, toluene, tetrahydrofuran, dichloromethane, chloroform, dioxane and acetonitrile.


In certain embodiments, the reaction of the phenol containing compound with the phosphorous containing compound occurs at 25° C. In other embodiments, the reaction of the phenol containing compound with the phosphorous containing compound occurs below 25° C. In other embodiments, the reaction of the phenol containing compound with the phosphorous containing compound occurs at a temperature between 25° C. and 0° C. In other embodiments, the reaction of the phenol containing compound with the phosphorous containing compound occurs at a temperature between 15° C. and 0° C. In other embodiments, the reaction of the phenol containing compound with the phosphorous containing compound occurs at a temperature between 5° C. and 0° C. In other embodiments, the reaction of the phenol containing compound with the phosphorous containing compound occurs at 0° C.


In certain embodiment, the reaction of the phenol containing compound with the phosphorous containing compound takes place under a nitrogen atmosphere.


In certain embodiments the reaction takes place over 5 hours. In certain other embodiment the reaction takes place in less than 5 hours. In certain other embodiments the reaction takes place in one hour. In certain other embodiment the reaction takes place in less than one hour. In certain other embodiments the reaction takes place for a period of 30 to 40 minutes.


In certain embodiment after completion of the reaction the suitable solvent is removed by distillation


In certain other embodiments after the suitable solvent is distilled off, the compound of the present invention are purified via crystallization using techniques known in the art.


In certain embodiments, after crystallization, the crystals are further filtered and washed using techniques known in the art.


Scheme 1 is a representative example of the synthesis of a compound of the present invention.


Scheme 1, Shows the Synthesis of a Sterically Hindered Phenol and Phosphite Based Compound of Structural Formula I.




embedded image


The macromolecular antioxidant S was synthesized by one pot reaction of phenol with phosphorous trichloride using dichloromethane as a solvent at 0° C. The yield of the title compound was more than 95%.


Scheme 2, Shows the Synthesis of a Sterically Hindered Phenol and Phosphite Based Compound of Structural Formula II.




embedded image



Scheme 3, Shows the Synthesis of a Sterically Hindered Phenol and Phosphite Based Compound of Structural Formula III.




embedded image


The following is an example of one embodiment of the invention and is not to be considered limiting in any way.


In one embodiment the sterically hindered phenol and phosphate based antioxidant is:




embedded image


EXEMPLIFICATION
Example 1
Preparation of tris[N-(4-hydroxyphenyl),-3-(2,6-di-tert.-butyl,4-hydroxyphenyl)propionamide]phosphite, S

A 1 L two-necked round bottom flask equipped with a thermometer, a dropping funnel and a nitrogen inlet was charged with 100 g (0.271 mole) of N-(4-hydroxyphenyl)-3-(2,6-di-tert-butyl, 4-hydroxy phenyl) propionamide, 22 ml (0.271 mole) pyridine in 200 ml of dichloromethane. 7.86 ml (9.033 mmol) of phosphorous trichloride was then added dropwise at a temperature of 0 to 5° C. under nitrogen atmosphere for a period of 30 to 40 minutes. After the addition, the funnel was removed and completion of the reaction was checked by TLC/HPLC. After completion, the dichloromethane was distilled out at 40° C. To the residue was added 100 ml of methanol to get white crystalline precipitate, which was then filtered and washed several times with cold methanol. The product was characterized by spectroscopic techniques. The melting point is in the range of 224-245° C.


Example 2
Stabilization of polypropylene by tris[N-(4-hydroxyphenyl),-3-(2,6-di-tert.-butyl,4-hydroxyphenyl)propionamide]phosphite S

1000 ppm of S was added to unstabilized polypropylene powder and extruded with single screw extruder in the form wires which was then palletized using a pelletizer. The pelletized sample of polypropylene was subjected to an accelerated oxidative stability test using differential scanning calorimetry (DSC) (ASTM D3895 method).


The results are shown in FIG. 1, which shows that tris[N-(4-hydroxyphenyl),-3-(2,6-di-tert.-butyl,4-hydroxyphenyl)propionamide]phosphite has a significantly higher oxidative induction time than commercially available Irganox®.


While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

Claims
  • 1. A compound represented by Structural Formula II:
  • 2. The compound of claim 1, wherein the compound is represented by the following structural formula:
RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 11/293,844, filed Dec. 2, 2005, which claims the benefit of U.S. Provisional Application No. 60/633,196, filed on Dec. 3, 2004. The entire teachings of the above applications are incorporated herein by reference.

US Referenced Citations (157)
Number Name Date Kind
3116305 Morris et al. Dec 1963 A
3294836 Peterson et al. Dec 1966 A
3441545 Blatz et al. Apr 1969 A
3459704 Peterson et al. Aug 1969 A
3557245 Phillips et al. Jan 1971 A
3632785 Bornstein Jan 1972 A
3645970 Kleiner Feb 1972 A
3649667 Song et al. Mar 1972 A
3655831 Friedman Apr 1972 A
3870680 Schurdak Mar 1975 A
3907939 Robin et al. Sep 1975 A
3953402 Kline Apr 1976 A
3965039 Chaplits et al. Jun 1976 A
3983091 Gloth et al. Sep 1976 A
3994828 Zaffaroni Nov 1976 A
3996160 Dale et al. Dec 1976 A
3996198 Wang et al. Dec 1976 A
4054676 Weinshenker et al. Oct 1977 A
4094857 Wolfe, Jr. Jun 1978 A
4096319 Willette et al. Jun 1978 A
4097464 Kline Jun 1978 A
4098829 Weinshenker et al. Jul 1978 A
4107144 Russell et al. Aug 1978 A
4136055 Lyons Jan 1979 A
4202816 Moser et al. May 1980 A
4205151 Dale et al. May 1980 A
4213892 Scott Jul 1980 A
4219453 Sakurai et al. Aug 1980 A
4267358 Hechenbleikner et al. May 1981 A
4281192 Jacquet et al. Jul 1981 A
4283572 Klicker Aug 1981 A
4317933 Parker Mar 1982 A
4341879 Sugio et al. Jul 1982 A
4355148 Layer et al. Oct 1982 A
4377666 Farrar Mar 1983 A
4380554 Serres, Jr. Apr 1983 A
4447657 Firth et al. May 1984 A
4465871 Firth et al. Aug 1984 A
4510296 Hergenrother Apr 1985 A
4511491 Ishii et al. Apr 1985 A
4634728 Dunski et al. Jan 1987 A
4690995 Keskey et al. Sep 1987 A
4761247 Rei et al. Aug 1988 A
4824929 Arimatsu et al. Apr 1989 A
4849503 Cotter et al. Jul 1989 A
4855345 Rosenberger et al. Aug 1989 A
4857596 MacLeay et al. Aug 1989 A
4870214 Mina et al. Sep 1989 A
4894263 Dubois et al. Jan 1990 A
4897438 Kikuchi et al. Jan 1990 A
4900671 Pokora et al. Feb 1990 A
4925591 Nakauchi et al. May 1990 A
4968759 Kikuchi et al. Nov 1990 A
4977004 Bettle, III et al. Dec 1990 A
4981917 MacLeay et al. Jan 1991 A
4994628 Goddard et al. Feb 1991 A
5013470 Benfaremo May 1991 A
5017727 Olivier May 1991 A
5082358 Tabata et al. Jan 1992 A
5102962 Kikuchi et al. Apr 1992 A
5117063 Stern et al. May 1992 A
5143828 Akkara et al. Sep 1992 A
5155153 Neri et al. Oct 1992 A
5185391 Stokich, Jr. Feb 1993 A
5185407 Wong Feb 1993 A
5188953 Johnson et al. Feb 1993 A
5191008 Frost et al. Mar 1993 A
5196142 Mollet et al. Mar 1993 A
5206303 Tse et al. Apr 1993 A
5207939 Farng et al. May 1993 A
5274060 Schadeli Dec 1993 A
5278055 Cyrus, Jr. et al. Jan 1994 A
5304589 Davidson et al. Apr 1994 A
5320889 Bettle, III Jun 1994 A
5449715 Plochocka et al. Sep 1995 A
5498809 Emert et al. Mar 1996 A
RE35247 Cyrus, Jr. et al. May 1996 E
5516856 Sanchez May 1996 A
5541091 Wheeler et al. Jul 1996 A
5565300 Uenishi et al. Oct 1996 A
5574118 Olivier Nov 1996 A
5652201 Papay et al. Jul 1997 A
5739341 Dubs et al. Apr 1998 A
5834544 Lin et al. Nov 1998 A
5837798 Hutchings et al. Nov 1998 A
5869592 Gagne et al. Feb 1999 A
5911937 Hekal Jun 1999 A
5994498 Tripathy et al. Nov 1999 A
6018018 Samuelson et al. Jan 2000 A
6046263 Rasberger et al. Apr 2000 A
6096695 Lam et al. Aug 2000 A
6096859 Akkara et al. Aug 2000 A
6150491 Akkara Nov 2000 A
6232314 Jarrott et al. May 2001 B1
6342549 Hirose et al. Jan 2002 B1
6444450 Akkara et al. Sep 2002 B2
6646035 Koch et al. Nov 2003 B2
6723815 Callaghan et al. Apr 2004 B2
6743525 Berntsen et al. Jun 2004 B2
6770785 Desai et al. Aug 2004 B1
6794480 Goto et al. Sep 2004 B2
6800228 Semen Oct 2004 B1
6828364 Gugumus Dec 2004 B2
7132496 Kerres et al. Nov 2006 B2
7169844 Inokami Jan 2007 B2
7205350 Thibaut Apr 2007 B2
7223432 Cholli et al. May 2007 B2
7262319 Rehm et al. Aug 2007 B2
7705176 Cholli et al. Apr 2010 B2
20010041203 Uno et al. Nov 2001 A1
20020007020 Higahimura et al. Jan 2002 A1
20020128493 Romanczyk, Jr. et al. Sep 2002 A1
20020143025 Pratt et al. Oct 2002 A1
20020183470 Tripathy et al. Dec 2002 A1
20030030033 Duyck et al. Feb 2003 A1
20030078346 Nakamura et al. Apr 2003 A1
20030091837 Aoki May 2003 A1
20030176620 Romanczyk, Jr. et al. Sep 2003 A1
20030191242 Zedda et al. Oct 2003 A1
20030229196 Braat et al. Dec 2003 A1
20030230743 Cholli et al. Dec 2003 A1
20040015021 Adams et al. Jan 2004 A1
20040164279 Stevenson et al. Aug 2004 A1
20040180994 Pearson et al. Sep 2004 A1
20040186167 Dou et al. Sep 2004 A1
20040186214 Li et al. Sep 2004 A1
20040198875 Kaprinidis et al. Oct 2004 A1
20040214935 Cholli et al. Oct 2004 A1
20050170978 Migdal et al. Aug 2005 A1
20050209379 Botkin et al. Sep 2005 A1
20050238789 Cholli et al. Oct 2005 A1
20050242328 Baranski Nov 2005 A1
20060029706 Cholli et al. Feb 2006 A1
20060040833 Al-Akhdar et al. Feb 2006 A1
20060041087 Cholli Feb 2006 A1
20060041094 Cholli Feb 2006 A1
20060128929 Yang et al. Jun 2006 A1
20060128930 Dhawan et al. Jun 2006 A1
20060128931 Kumar et al. Jun 2006 A1
20060128939 Kumar et al. Jun 2006 A1
20060154818 Destro et al. Jul 2006 A1
20060189820 Rehm et al. Aug 2006 A1
20060189824 Kumar et al. Aug 2006 A1
20060208227 Shiraki Sep 2006 A1
20060233741 Kumar et al. Oct 2006 A1
20070010632 Kaplan et al. Jan 2007 A1
20070106059 Cholli et al. May 2007 A1
20070135539 Cholli et al. Jun 2007 A1
20070149660 Kumar et al. Jun 2007 A1
20070154430 Cholli et al. Jul 2007 A1
20070154608 Cholli et al. Jul 2007 A1
20070154720 Cholli et al. Jul 2007 A1
20070161522 Cholli et al. Jul 2007 A1
20080249335 Cholli et al. Oct 2008 A1
20080293856 Kumar et al. Nov 2008 A1
20080311065 Cholli Dec 2008 A1
20090184294 Cholli et al. Jul 2009 A1
Foreign Referenced Citations (58)
Number Date Country
111291 Jun 1964 CS
197 47 644 May 1999 DE
198 43 875 Mar 2000 DE
0 181 023 May 1986 EP
0 289 077 Nov 1988 EP
0 358 157 Mar 1990 EP
0 404 039 Dec 1990 EP
0 618 203 Oct 1994 EP
0 688 805 Dec 1995 EP
1 067 144 Jan 2001 EP
1 468 968 Oct 2004 EP
2 183 973 Jan 1974 FR
1 283 103 Jul 1972 GB
1 320 169 Jun 1973 GB
1 372 042 Oct 1974 GB
1 389 442 Apr 1975 GB
1 469 245 Apr 1977 GB
1 482 649 Aug 1977 GB
69002715 Jan 1966 JP
43016392 Jul 1968 JP
44024274 Oct 1969 JP
44028850 Nov 1969 JP
45 2980 Jan 1970 JP
49 29339 Mar 1974 JP
57085366 May 1982 JP
59025814 Feb 1984 JP
59197447 Nov 1984 JP
60-199832 Oct 1985 JP
05 199858 Aug 1993 JP
06135876 May 1994 JP
06 247959 Sep 1994 JP
08027226 Jan 1996 JP
09262069 Oct 1997 JP
09 328519 Dec 1997 JP
09 328521 Dec 1997 JP
9322784 Dec 1997 JP
11-80063 Mar 1999 JP
11-158103 Jun 1999 JP
2003138258 May 2003 JP
7 905 000 Mar 1980 NL
WO 9220734 Nov 1992 WO
WO 0039064 Jul 2000 WO
WO 0118125 Mar 2001 WO
WO 0148057 Jul 2001 WO
WO 02079130 Oct 2002 WO
WO 03087260 Oct 2003 WO
WO 03102004 Dec 2003 WO
WO 2004024070 Mar 2004 WO
WO 2004050795 Jun 2004 WO
WO 2005025513 Mar 2005 WO
WO 2005025646 Mar 2005 WO
WO 2005060500 Jul 2005 WO
WO 2005070974 Aug 2005 WO
WO 2005071005 Aug 2005 WO
WO 2006018403 AI Feb 2006 WO
WO 2006060801 Jun 2006 WO
WO 2006104957 Oct 2006 WO
WO 2008005358 Jan 2008 WO
Related Publications (1)
Number Date Country
20100305361 A1 Dec 2010 US
Provisional Applications (1)
Number Date Country
60633196 Dec 2004 US
Continuations (1)
Number Date Country
Parent 11293844 Dec 2005 US
Child 12789843 US